SAFETY AND EFFICACY OF LONG-TERM THERAPY WITH HIGH DOSES OF ATORVASTATIN


M.V. Ezhov, E.V. Sorokin

SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI “National Medical and Research Center of Cardiology”of RMH, Moscow
Cardiovascular diseases of atherosclerotic origin make a significant contribution to morbidity and mortality in Russian Federation. Hypercholesterolemia is the leading risk factor for the development of coronary artery disease (CAD). The case of early CAD due to heterozygous familial hypercholesterolemia and successful achievement of the target level of low-density lipoprotein cholesterol with the use of the maximum dose of atorvastatin and the subsequent stabilization of the course of CAD are analyzed. The original atorvastatin (Liprimar), due to the unique evidence base of randomized clinical trials conducted in patients with a very high cardiovascular risk, a reference drug with the possibility of prolonged and safe use at the maximum dosage.

About the Autors


Corresponding author: M.V. Ezhov – MD, Cardiologist, Leading Researcher at the Department of Atherosclerosis Problems SRI of Clinical Cardiology n.a. A.L. Myasnikov, FSBI NMRCC of RMH, Moscow; e-mail: Marat_Ezhov@mail.ru


Similar Articles


Бионика Медиа